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1. Introduction 
1.1 Telomeres and tumorigenesis  
1.1.1 Telomere structure  
Human chromosomes, which are composed of linear double-stranded DNA, are capped at 
their ends by nucleoprotein complexes called telomeres (reviewed in (Martinez & Blasco, 
2011)). This telomeric cap prevents end-to-end fusion events between chromosomes, and 
protects chromosome ends from being recognized as double-stranded breaks by the DNA 
damage machinery in the cell. Telomeric DNA is composed of tandem 5’TTAGGG repeats at 
each end of the chromosome, extending up to tens of kilobases. Poorly understood end-
processing reactions after replication result in a 3’ overhang on the G-rich strand, which 
invades the upstream double-stranded telomeric DNA to form a displacement (D)-loop such 
that the end of the chromosome is buried thereby preventing detection by the cellular DNA 
damage response (Greider, 1999). Telomeric DNA is in complex with a number of proteins 
that act to stabilize the structure and mediate telomeric functions of capping and length 
regulation (Figure 1). Double-stranded (ds) telomeric repeats are bound directly by TRF1 
(Zhong et al., 1992) and TRF2 (Bilaud et al., 1997; Broccoli et al., 1997), while the POT1-TPP1 
heterodimer binds to the single-stranded (ss) telomeric DNA (de Lange, 2005; Lei et al., 
2002). The ds- and ss-telomeric DNA complexes are linked through their interaction with 
TIN2 (Abreu et al., 2010; Kim et al., 1999; O'Connor et al., 2006), together forming the 
telomeric shelterin complex (de Lange, 2005). Additional proteins necessary for telomeric 
function are recruited by interactions with components of the shelterin complex (reviewed 
in (Martinez & Blasco, 2011)).  
Mammalian telomeres have been shown to contain characteristics of heterochromatin, 
including the presence of homologues of the heterochromatin binding protein HP1 (Koering 
et al., 2002; Sharma et al., 2003), enriched tri-methylation of histone H3 lysine 9 (H3K9) and 
histone H4 lysine 20 (H4K20) (Garcia-Cao et al., 2004), and methylation of CpG 
dinucleotides in subtelomeric DNA repeats (Gonzalo et al., 2006). Studies in telomerase 
knockout mice demonstrated that as telomeres become shorter the heterochromatic marks 
are lost and replaced by marks characteristic of open chromatin, such as increased 
acetylation of histone tails (Benetti et al., 2007),  suggesting that a minimum telomere length 
is necessary to maintain the appropriate chromatin structure at chromosome ends. 
Alterations in the level of epigenetic modifications, such as tri-methylation of H3K9 and 
H4K20 via knockout of the relevant modifying enzymes, led to increased telomere length 
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without effect on telomere end-capping function (Garcia-Cao et al., 2004). Intriguingly, 
evidence of increased telomeric recombination is also a result of altering telomeric 
chromatin structure (Gonzalo et al., 2006).  
 
 
Fig. 1. Proteins of the shelterin complex. TRF1 and TRF2 bind directly to double-stranded 
telomeric sequence, with TRF2 recruiting RAP1. The POT1-TPP1 binds to single-stranded 
regions. Interactions with TIN2 link the single-stranded and double-stranded binding 
complexes. 
Despite having chromatin features characteristic of heterochromatin, telomeres are now 
known to be transcriptionally active, giving rise to a species of long non-coding RNA 
(lncRNA) termed TERRA (Luke & Lingner, 2009). Long non-coding RNAs are involved in 
establishing and maintaining chromatin structure (Whitehead et al., 2009). TERRA has been 
suggested to play a role in telomere heterochromatin formation (Deng et al., 2009). TERRA 
associates with telomeres and may be involved in maintaining or remodeling telomere 
structure during development and differentiation (Luke & Lingner, 2009). 
1.1.2 Telomere dynamics  
Linear DNA molecules use RNA to prime replication by DNA polymerase. At the 
completion of synthesis, these primers are degraded and gaps are filled, but the regions at 
the 5’ ends of the newly synthesized strands cannot be filled in. Thus, with each replication 
cycle, telomeric sequences shorten at their 5’ ends (Figure 2). End processing events 
subsequent to replication (Sfeir et al., 2005) may also contribute to sequence loss. Excessive 
shortening of telomeres disrupts the shelterin complex through loss of binding sites for 
shelterin complex proteins, which exposes chromosome ends to DNA damage machinery. In 
the presence of an active DNA damage response (DDR), telomere uncapping activates DNA 
damage checkpoints, leading to cell cycle arrest or apoptosis (Martinez & Blasco, 2011). 
Thus, telomere length acts as a molecular clock, limiting the total number of divisions any 
given cell may undergo. In the absence of a robust DDR, such as often occurs on the road to 
transformation, exposed telomere ends result in increased genomic instability through 
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breakage-fusion-bridge cycles induced by joining of chromosome ends. This ‘telomere crisis’ 
can only be resolved by restoring telomeres to a length sufficient for functional shelterin 
complex assembly. Therefore, to circumvent the effects of telomere attrition and attain 
unlimited replicative potential, cancer cells must solve the so-called ‘end replication 
problem.’   
 
 
Fig. 2. Telomere attrition from subsequent cell divisions continues until critically short 
telomeres result in a DNA damage response and the cessation of cell division. In cancer 
cells, mutations in key regulatory proteins block DNA damage signaling, allowing cell 
division to continue, potentially leading to chromosome rearrangements from chromosome 
end-to-end fusions. 
Telomere extension occurs by activation of a telomere maintenance mechanism (TMM), via 
either telomerase or a recombination-based mechanism called alternative lengthening of 
telomeres (ALT). Activation of either mechanism is sufficient to recover from telomere crisis, 
thus enabling continued growth of the cancer cells. Resolution of telomere crisis is not a 
prerequisite to tumor formation, however, as some adult cells contain adequate telomeric 
reserves to form tumors requiring clinical intervention before loss of telomeric DNA 
becomes sufficient to induce crisis (Reddel, 2000). Nevertheless, telomere attrition will 
ultimately limit tumor growth. TMM activation, because it increases replicative potential, is 
often associated with higher grade tumors and poorer patient prognosis (Costa et al., 2006; 
Matsuo et al., 2009; Ulaner et al., 2003). Indeed, progress through telomere crisis with its 
associated genome instability has been suggested to contribute to tumorigenicity by 
generating a hypermutability environment (Chin et al., 2004), analogous to the tumorigenic 
potential of cells with microsatellite instability. 
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2. Telomere maintenance mechanisms  
2.1 Telomerase  
Telomerase is a ribonucleoprotein complex that adds telomeric DNA de novo onto 
chromosome ends (Greider & Blackburn, 1987). The catalytic component of the holoenzyme, 
TERT, is a reverse transcriptase (RNA-dependent DNA polymerase) that uses the RNA 
component, TR (aka TERC), as a template for telomere extension (Figure 3). Telomerase is 
commonly active in germline and some stem cell populations (Artandi & DePinho, 2010), 
ensuring species-specific telomere length and sufficient reserves to complete developmental 
programs, respectively. In addition, telomerase may be transiently active during certain 
differentiation programs (Hodes et al., 2002), leading to regulated telomere extension prior 
to expansion. Telomerase activity is not enough to entirely prevent telomere attrition over 
an individual’s lifetime (Martinez & Blasco, 2011). Furthermore, stressing stem cell 
compartments, for example as occurs following bone marrow transplantation, may 
contribute to premature aging of differentiated cells arising from those stem cell 
compartments (Allsopp et al., 2001; Lewis et al., 2004). Most differentiated cells do not 
express hTERT and therefore lack telomerase activity. Expression of telomerase, while 
conferring immortality on cells, is not directly tumorigenic with transformation requiring 
additional genetic changes (Bodnar et al., 1998; Hahn et al., 1999; Vaziri & Benchimol, 1998). 
However, as discussed above, acquisition of telomere length stabilization removes a critical 
tumor suppressor mechanism. Activation of telomerase is the primary TMM in most 
carcinomas as well as translocation-associated sarcomas. 
Experimentally, telomerase activity is determined through an assay called the telomere 
repeat amplification protocol (TRAP) (Kim et al., 1994). In this assay, protein extracts are 
incubated with a short oligonucleotide that can be extended by telomerase, if it is present. 
After PCR amplification and acrylamide gel electrophoresis of products, extracts containing 
active telomerase will show a ladder of products with increasing numbers of telomeric 
TTAGGG repeats. The presence of active telomerase in the extract does not necessitate 
cellular activity, as in vitro activity can be achieved without the additional factors required in 
vivo to support extension of chromosome ends. Indeed, mutants that are catalytically active 
in vitro but unable to maintain telomeres in vivo, have been described (Counter et al., 1998) 
and highlight the multiple levels of regulation associated with telomere maintenance by 
telomerase (Osterhage & Friedman, 2009). The absence of activity by TRAP is also not 
definitive, as telomerase activity can be easily destroyed by technical challenges during 
extract isolation and soluble inhibitors of either the initial extension reaction or the PCR 
amplification step may be present. A definitive lack of activity can be attained by 
demonstrating the absence of the TERT mRNA by quantitative PCR, as activity cannot occur 
in the absence of the catalytic component of telomerase. 
2.2 ALT  
Alternative lengthening of telomeres is an umbrella term for all non-telomerase mechanisms 
for telomere maintenance (Cesare & Reddel, 2010; Henson & Reddel, 2010). Telomeres in 
ALT cells are often heterogeneous in length, ranging from very short (<6 kb) to very long 
(>20 kb), which are easily visualized either by southern blot or quantitative FISH. Despite 
the broad range of sizes, the average telomere length, as measured by quantitating southern 
blots, is longer than that observed in normal adult or telomerase-positive cancers (Bryan et 
al., 1995). ALT cells also frequently show mini-satellite instability (Jeyapalan et al., 2008; 
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Jeyapalan et al., 2005) and increased telomere sister chromatid exchange (T-SCE) (Londono-
Vallejo et al., 2004), which presumably arises from increased recombination at telomeres. 
Both assays are of limited use in tumor tissue as the mini-satellite instability assay requires 
the ability to PCR long (~4KB) DNA fragments that may have significant degradation in 
archival tumor samples and the T-SCE assay relies on the ability to label cells in culture. 
Also found in ALT cells are double-stranded circular DNA molecules called t-circles that are 
generated from telomeric DNA and may function in telomere elongation via recombination-
independent rolling circle replication (Tomaska et al., 2004). Single-stranded circles, called 
either c-circles or g-circles based on sequence, are also present in these cells, with c-circles 
being much more abundant (Henson et al., 2009). The ability to detect these circles with high 
specificity in archival tumor tissue has not been demonstrated. Perhaps the most frequently 
assayed characteristic of ALT cells is the appearance of ALT associated PML bodies (APBs), 
in which telomeric DNA co-localizes with the PML nuclear body (Yeager et al., 1999).  
The role of APBs in ALT remains controversial. Conflicting reports have suggested that 
APBs are a marker of ALT cells that are irreversibly arrested or, conversely, are required for 
telomere maintenance by ALT. Early studies of ALT-positive cell lines immortalized in vitro 
suggested that perturbation of the p53 pathway might be a common element (Opitz et al., 
2001; Rogan et al., 1995). We have previously demonstrated that forced expression of a 
transactivation-dead p53 suppresses growth of ALT-positive, but not telomerase positive, 
cells (Razak et al., 2004). We reported that this caused an increase in APB frequency in the 
absence of downstream effectors of p53, such as p21. We concluded that abrogation of p53 
suppression of recombination function was required for ALT activation. In contrast, the 
Reddel group has reported that over-expression of transactivation competent p53 leads to 
an increase in APBs, and that this increase in APBs requires p21 (Jiang et al., 2009). These 
authors conclude that APBs arise in arrested cells rather than cells undergoing telomere 
elongation by recombination. Furthermore, although ATM is constitutively active in p53-
positive ALT-positive cell lines, activation of p53 and downstream effectors only occurs 
when telomeres are uncapped via perturbation of the shelterin complex (Stagno D'Alcontres 
et al., 2007). PML is essential for p21 induced cellular senescence in this context, although it 
is not required for p53 to associate with telomeres.  
In contrast to experiments suggesting that APBs only occur in arrested cells, we and others 
have shown that DNA replication occurs in APB-positive cells, suggesting that these 
structures are present in actively cycling cells (Grobelny et al., 2000). Others have found that 
disruption of APBs prevents telomere maintenance by ALT and leads to loss of culture 
viability, arguing for an active role of APBs in telomere maintenance by ALT (Jiang et al., 
2005). The spatio-temporal dynamics of telomeric DNA association with PML bodies have 
been recently described, and the authors of this study conclude that telomere recombination 
takes place in these structures (Draskovic et al., 2009). Furthermore, new PML bodies form 
at telomeric DNA regardless of which TMM is active (Brouwer et al., 2009) and APBs form 
transiently in human diploid fibroblasts following high LET radiation (Berardinelli et al., 
2010), suggesting that the association of telomeric DNA with PML bodies may be a 
component of a DNA damage response. Indeed, telomeres are transiently recognized as 
DNA damage during normal DNA replication (Verdun & Karlseder, 2006). The consistent 
theme within these data is that uncapped/short telomeres are localized to the PML body.  
TERRA expression is increased in ALT cell lines and is accompanied by a less dense, albeit 
variable, pattern of sub-telomeric CpG methylation relative to telomerase positive and 
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normal cells (Ng et al., 2009). It is not clear if the increase in TERRA occurs subsequent to 
altered sub-telomeric chromatin (i.e., as a consequence) or contributes to generating changes 
in sub-telomeric chromatin (i.e., as a cause). Recent work implicates TERRA as being critical 
for telomere structure in the ALT-positive U2OS cell line and telomerase positive HCT116 
cells (Deng et al., 2009). TERRA was shown to interact with the end-capping protein TRF2, 
and decreasing TERRA expression levels led to loss of heterochromatin marks and telomere 
instability. On the surface, then, one might expect the increased TERRA in ALT cells to 
increase heterochromatin-associated chromatin condensation making telomeres less 
accessible to recombination. Conversely, we have shown that TERRA levels increase as 
telomeres shorten (associated with gaining histone marks consistent with an open chromatin 
structure) and in response to telomere uncapping (Caslini et al., 2009). The increase in 
TERRA, in this context, requires activity of the histone H3K4 methyltransferase MLL and 
the p53 DNA damage response. How might these observations be reconciled?   It is likely 
based on published results that a minimum level of TERRA expression is necessary to 
support functional end-capping. However, TERRA may play additional roles in ALT-
positive cells. Increased TERRA may be necessary to propagate and maintain a more open 
chromatin structure, which in turn promotes telomeric recombination, by titrating essential 
factors and modulating the formation of telomeric heterochromatin. Alternatively, increased 
TERRA in ALT cells may simply reflect the presence of ultra-long telomeres present in these 
cells. Future studies will elucidate the role of TERRA in telomere stability and telomere 
maintenance mechanisms. 
Many questions remain about the nature of the ALT mechanism. A single ALT cell may 
show only some of the features associated with ALT, and may show a different subset of 
features than other ALT cells (Fasching et al., 2005; Slatter et al., 2010). This may result from 
the existence of multiple mechanisms currently described as ALT. It is unclear to what 
extent these different mechanisms rely on similar or overlapping pathways for telomere 
maintenance, and thus whether and to what extent they share genetic requirements for 
activation and regulation. For example, if the appearance of APBs is related to DNA damage 
and repair, does the lack of APBs in some ALT cells indicate lower levels of DNA damage 
and thus lower levels of genome instability? Or are APBs associated with a specific 
recombination-based pathway for telomere maintenance?  An essential step on the pathway 
to understanding ALT regulation, and the pathways leading to telomere stabilization 
through recombination, would be the development of an ALT cell line lacking APBs. It 
remains essential as further work is done to characterize ALT to be cognizant of the 
potential impact the features used to define cells as ALT-positive have on any conclusions 
about the characteristics of ALT in general. 
ALT seems to be more common in tumors of mesenchymal origin and with complex 
karyotypes when compared to those of epithelial origin and translocation-driven, 
respectively (Johnson & Broccoli, 2007; Montgomery et al., 2004; Ulaner et al., 2004), which 
may provide some insight into the genetic origins of ALT. Both ALT and telomerase can be 
active in a single tumor (Costa et al., 2006; Hakin-Smith et al., 2003; Johnson et al., 2005; 
Ulaner et al., 2003), suggesting that lack of functional telomerase is not a prerequisite for 
ALT activation, although it is not known whether both mechanisms can be active in a single 
cell. Studies investigating TMM in tumors rely upon a variety of assays to identify 
telomerase-positive and ALT-positive tumors, respectively (Costa et al., 2006; Montgomery 
et al., 2004; Ulaner et al., 2003). At least some of the tumors without characteristics of either 
mechanism are also ALT-positive based upon increased mini-satellite instability (Jeyapalan 
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et al., 2008; Jeyapalan et al., 2005). However, a substantial fraction of mesenchymal tumors 
defy TMM characterization using the currently available techniques. In part this is due to 
many assays not being consistent with the quality of DNA isolated from tumor tissue, 
particularly archival tissues that are only available as formalin-fixed, paraffin-embedded 
samples. An alternative possibility is that only a rare subset of tumor cells, e.g. tumor stem 
cells, actively maintain telomeres while the bulk of the cells comprising the tumor do not 
have active telomere maintenance.  
3. Telomere maintenance mechanisms in tumorigenesis  
Although it is used in a considerable proportion of cell lines (~35%), until recently ALT had 
only rarely been documented in human tumors (Bryan et al., 1997). Accordingly, 
comparative studies have relied largely upon cell culture systems or investigation of tumors 
arising in late generation telomerase-deficient mouse models, which are thus forced to use 
ALT. Although each system has inherent limitations with respect to extrapolation to human 
cancer, several key insights have come from these studies. Most importantly, the two 
mechanisms of telomere maintenance are not equivalent with respect to their contribution to 
the tumorigenic phenotype. Exogenous expression of hTERT, the catalytic subunit of 
telomerase, in combination with activated Ras and the SV40 early region is sufficient to 
transform human cells and render them tumorigenic in nude mice (Hahn et al., 1999). In 
contrast, human cells which rely on ALT instead of telomerase for telomere maintenance, 
while immortal, are unable to form tumors in nude mice when injected subcutaneously, 
although they are competent to form tumors when injected under the renal capsule (Sun et 
al., 2005). If hTERT is introduced into these cells, tumorigenicity is restored in the 
subcutaneous setting even though telomerase is not required for telomere maintenance per 
se. Likewise, immortalized mouse embryo fibroblasts (MEFs) that use telomerase are readily 
able to colonize lungs and proliferate when injected into tail veins, while MEFs that use ALT 
are not (Chang et al., 2003). Thus, while telomere maintenance by either TMM is sufficient to 
ensure replicative immortality, these studies suggest that telomerase may provide 
additional growth advantages during in vivo tumorigenesis.  
Both ALT and telomerase can be active in a single tumor, suggesting that lack of functional 
telomerase is not a prerequisite for ALT activation, although it is not known whether both 
mechanisms can be active in a single cell. Given tumor heterogeneity it is possible that 
distinct regions of a tumor utilize telomerase and ALT respectively. In cell based studies in 
which telomerase expression was forced in an ALT background, telomerase specifically 
elongated the shortest telomeres in the population (Grobelny et al., 2001). Despite extensive 
culturing, characteristics of ALT such as APBs were not altered in the presence of 
telomerase. This suggests that reconstitution of telomerase, and associated telomere 
stabilization, is not sufficient to suppress the ALT mechanism once it has been activated. 
4. Telomere maintenance mechanisms in liposarcomas  
Soft tissue sarcomas (STS) are rare malignancies of mesenchymal origin, with approximately 
10 500 cases in 2010 (Jemal et al., 2010). Given the rarity of mesenchymal tumors, studies 
assessing TMM activation have either used multiple histological types or focused on the 
more common STS types. The most common adult STS, accounting for ~20% of cases, is 
liposarcoma, named for its morphological resemblance to adipose tissue. Liposarcomas are 
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divided into several subtypes based on histological features: well-differentiated (WDLS), de-
differentiated (DDLS), pleomorphic (PLS), myxoid (MYXLS), and round cell (RCLS). Based 
upon expression profiling, it has been suggested that these tumors can be further classified 
along a developmental pathway from the mesenchymal stem cell to mature adipocytes 
based on their state of differentiation (Matushansky et al 2008), with de-differentiated 
liposarcomas most closely resembling mesenchymal stem cells, and well-differentiated 
liposarcomas most closely resembling mature adipocytes. The remaining histotypes fall 
between these, with pleomorphic liposarcomas appearing less differentiated than 
myxoid/round cell tumors. Due to their relatively high frequency among adult STS, several 
studies of TMM have focused on liposarcomas. Intriguingly, the frequency of specific TMM 
utilization appears to vary with histological subtype within this category of STS (Figure 3). 
 
 
Fig. 3. TMM utilization varies among histological subtypes of liposarcoma. 
WD/DDLS together account for 55% of all LS (40% and 15% respectively) (Conyers et al., 
2011). Both WDLS and DDLS may contain a diagnostic Chr12q13-15 amplification (Rieker et 
al., 2010; Tap et al., 2011), although this genetic change is found more frequently in DDLS. 
WDLS are not typically included among the complex karyotype malignancies; however, 
upon dedifferentiation this tumor is included in the complex karyotype subdesignation. 
Combined, these tumors are called atypical lipotomous tumors, which, like alternative 
lengthening of telomeres, is commonly abbreviated ALT. WDLS are low grade tumors that 
are histologically similar to adipose tissue, showing primarily local recurrence with limited 
metastasis, in contrast to DDLS, which are higher grade tumors with greater propensity for 
metastasis. The WD/DDLS that have an active TMM use ALT and telomerase with similar 
frequency, but WDLS have a higher fraction of malignancies with no evidence of telomere 
maintenance (75% for WDLS, 50% for DDLS) (Costa et al., 2006). 
MYX/RC LS, which together account for ~40% of all LS, are characterized by the 
TLS/CHOP (aka FUS/CHOP) translocation (Conyers et al., 2011). This translocation is 
transformative when over-expressed in mice (Perez-Losada et al., 2000) and other cell lines 
(Riggi et al., 2006; Schwarzbach et al., 2004), indicating that FUS/CHOP drives 
tumorigenesis in these malignancies. Of the two, MYX LS is the lower grade, and RC LS is 
the higher grade. To our knowledge, no malignancies containing the characteristic 
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translocation have been shown to use ALT. Thus, if one uses this molecular alteration to 
classify MYX/RC LS, then these tumors use only telomerase for telomere maintenance. This 
is consistent with early reports suggesting that, as a whole, translocation-associated 
sarcomas utilize telomerase, rather than ALT, for telomere maintenance.  
The rarest form of liposarcoma, PLS, accounts for only 5% of all LS cases (Conyers et al., 2011). 
Like WD/DDLS, PLS is a complex karyotype malignancy. Unlike the lower grade tumors, PLS 
are highly metastatic and do not contain the chromosome 12q13-15 amplification characteristic 
of DDLS. Thus far, no PLS tested in our hands have shown telomerase activity, using the 
stringent criteria of not only absence of enzymatic activity using TRAP but also absence of 
hTERT expression. Using the presence of APBs as a marker for ALT activation, we have found 
that PLS exclusively use ALT for telomere maintenance or fall in the category of tumors 
without evidence of either pathway. Given the advanced nature of PLS, their high likelihood 
to metastasize relative to other types of liposarcoma, and poor prognosis for patients (Guillou 
& Aurias, 2010), it is likely that these tumors have active telomere maintenance even in the 
absence of APBs. However, the rarity of PLS has limited the ability to test this hypothesis as 
most tumors are only available as archival formalin-fixed, paraffin-embedded samples, which 
will not provide DNA of sufficient size to allow testing for microsatellite instability. Archival 
samples are also not amenable to analysis for T-SCE, which requires hemi-substitution of the 
DNA molecule with BrdU and therefore dividing cells. Additional markers of ALT 
activation/utilization await a better understanding of the various recombination-based 
pathways utilized for telomere maintenance.  
4.1 Genome instability and TMM  
Telomeres serve the essential function of providing stability to the ends of linear 
chromosomes. The cyclical behavior of a single marked telomere in ALT cells (gradual 
shortening over time in culture, punctuated by rapid increases in length and resumption of 
telomere attrition) suggests that ALT may act after telomeres reach a critically short length. 
Thus, it is possible that a steady state level of compromised telomere function might be a 
feature of cells that utilize ALT for telomere maintenance. Consistent with this possibility, a 
number of chromosome ends in any given metaphase cell of ALT-positive cell lines do not 
contain detectable telomeric DNA when analyzed by FISH (Cerone et al., 2001; Perrem et al., 
2001). Furthermore, comparison of osteosarcoma-derived cell lines that used either ALT or 
telomerase for telomere maintenance, using both telomere and multiplex fluorescence in-
situ hybridization (FISH), revealed telomere length heterogeneity and increased 
chromosomal rearrangements in ALT-positive cell lines compared to telomerase-positive 
cell lines (Scheel et al., 2001). One phenotype exhibited by cells that have lost telomere end-
protection function is the end-to-end fusion of chromosomes (Counter et al., 1992; van 
Steensel et al., 1998). During anaphase, these fusions are manifested as bridges of 
unresolved DNA between the separating daughter nuclei. Although such bridges can also 
arise through telomere independent mechanisms, an increase in anaphase bridges is 
characteristic of the loss of telomere capping function (Blasco et al., 1997; van Steensel et al., 
1998). It is noteworthy that ALT-positive sarcomas that were identified in archival sections 
by virtue of having APBs are reported to have higher levels of genome instability as 
measured by anaphase bridge index (Montgomery et al., 2004). These tumors also tended to 
have a complex karyotype. In contrast, tumors with translocations were predominantly non-
ALT (i.e., APB negative) and had lower instability.  
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As discussed above, shortening of telomeres leads to DNA damage and fusion-bridge-break 
cycles that result in increased genome instability in cancer cells with compromised DNA 
damage response. We previously reported that tumors using ALT for telomere maintenance 
have, on average, higher levels of genome instability than those using telomerase, and that 
tumors with any TMM active have, on average, higher genome instability than those falling 
in the category without evidence of either telomerase or ALT (Johnson et al., 2007). Genome 
instability in this study was defined as the percentage of SNPs deviating from diploid copy 
number. Intriguingly, genome instability was also increased in peritelomeric regions in ALT 
tumors, i.e., within 200 kb of the most telomeric SNP. These results are consistent with many 
tumors passing through telomere crisis prior to activation of a TMM.  
We have re-evaluated our conclusions regarding genome instability as a function of TMM in 
the light of our recent realization of histological bias in TMM. Of the 32 tumors included in 
the study, 9 used ALT, 6 used telomerase, 1 used both ALT and telomerase, and 16 did not 
show characteristics of either mechanism. Within each category, tumors are distributed 
among multiple histological types, minimizing the effect of histology. Thus, it is likely that 
the differences observed in genome instability between ALT and TEL occur despite 
differences in histological bias rather than because of it. The more uniform telomere length 
and DNA damage protection conferred by telomerase may help control genome instability 
in telomerase-positive tumors.  
4.2 TMM and survival  
Previous work has shown a link between ALT activation and decreased survival in 
liposarcomas (Costa et al., 2006). The authors of this study did consider the potential 
contribution of histological type to this result, and concluded that the survival decrease 
associated with ALT was significant even when tumor grade, location, and histotype were 
taken into account. It is unclear from the methods in the paper how these factors were 
accounted for in the statistics. What is clear is that approximately two thirds (20/33) of the 
ALT-positive tumors are DDLS/other (potentially PLS), and greater than two thirds (27/34) 
of the telomerase-positive tumors are MYX/RC. Thus, this tumor set contains a histological 
bias. The authors do note that histology still needs to be considered when interpreting their 
multivariable analysis given the obvious bias. Further, they comment that the reduced 
prognostic value of telomerase-positivity is due to round cell tumors already having poor 
prognosis. This study, therefore, highlights the need for single histotype (and possibly even 
single-grade) data for survival.  
In light of the discussion above regarding differences in characteristics of ALT-positive cell 
lines, it is important to note that Costa et al. defined tumors with 0.5% of nuclei containing 
APBs as ALT-positive. This is a fairly relaxed definition as co-localization of telomeric 
components with PML nuclear bodies is assayed by immunofluorescence and there is a 
possibility that signals will overlap by chance. We define ALT-positive as tumors in which 
at least 35% of the nuclei exhibit co-localization of telomeric components and PML nuclear 
bodies. This criterion is likely overly stringent and will exclude some ALT-positive tumors. 
Some of the differences may be resolved if clear criteria could be established to ensure a 
rigorous and consistent definition for APB-positive (and therefore ALT-positive) cells. 
We recently performed a new analysis of the relationship between histotype, TMM, and 
survival, using 52 tumors from complex karyotype liposarcomas (WDLS, DDLS, PLS). Our 
analysis did not include any myxoid/round cell tumors, which comprised about a third of 
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the samples in the earlier work. Consistent with the previous study, tumors that had 
activated a telomere maintenance mechanism were associated with poorer survival, but the 
survival difference between ALT and telomerase tumors was not significant (p=0.06). 
However, as the majority of tumors with a detectable TMM are higher grade, i.e., DDLS and 
PLS, it is possible that the difference in survival observed between TMM-positive and TMM-
negative tumors reflects differences in tumor grade rather than an independent marker of 
patient prognosis. Within DD-LS, which use both TMMs with similar, high frequency, there 
was no survival difference associated with TMM (p = 0.64). Thus, it is possible that the 
apparent poorer prognosis for ALT seen in the larger population is biased by higher grade 
pleomorphic tumors that contribute only to the ALT survival data. 
4.3 Genetic characterization of ALT versus telomerase-positive tumors  
It has been reported that the hTERT promoter is repressed in mesenchymal stem cells 
(Zimmermann et al., 2003). In cell based studies, epigenetic silencing of hTERT expression 
has also been documented (Serakinci et al., 2006). Thus, it is possible that the increased use 
of ALT in mesenchymal tumors is a result of tight repression of hTERT expression in this 
lineage.  
The observation of TMM-based differences in survival suggested that fundamental genetic 
differences might be present between telomerase-positive and ALT-positive tumors. In a 
genome-wide screen of liposarcomas, we identified deletion of Chr 1q32.4-44 as an ALT 
associated genetic alteration (Johnson et al., 2007). This deletion differentiates between 
telomerase positive and ALT-positive DDLS. It is also present in ALT-positive (i.e. APB-
positive) PLS. This is a large deletion containing many genes that might be implicated in 
tumorigenesis. When prioritized on the basis of known biological activity, SMYD3 stands 
out. SMYD3 is a methyltransferase that modifies histone H3 on lysine 4 (H3K4) (Hamamoto 
et al., 2004). Methylation of H3K4 is found at actively transcribed regions in the genome 
(Eissenberg & Shilatifard, 2010). In fact, this chromatin mark is associated with the 5’ end of 
transcribed genes. Increased SMYD3 expression is associated with advanced cancers while 
reducing SMYD3 levels inhibits cancer cell growth and promotes apoptosis in vitro  (Chen et 
al., 2007; Hamamoto et al., 2004; Hamamoto et al., 2006). Comparion of the expression 
profiles of cells with forced SMYD3 expression to cells with unaltered SMYD3 levels found 
alterations consistent with tumor progression, including activation of NF-kB pathway genes 
(Yamamoto et al., 2011). SMYD3 has recently been reported to be important for epigenetic 
modification of the hTERT promoter resulting in transcription of this locus (Liu et al., 2007). 
Importantly, over-expression of SMYD3 in both primary human fibroblasts and ALT-
positive Saos-2 cells resulted in telomerase expression while siRNA-mediated knockdown 
led to inhibition of hTERT gene expression. However, hTERT expression does not 
necessarily lead to enzymatic activity capable of stabilizing telomeric repeats because, as 
discussed above, both telomerase activity and access to telomeres are regulated at multiple 
levels. In addition, ectopic SMYD3 expression likely affected multiple sites within the 
genome. Finally, SMYD3 expression in tumors utilizing different TMMs was not assessed. 
Thus, the relevance of SMYD3 deletion to ALT utilization in human tumors is not yet 
established. 
Levels of H3K4 methylation at mammalian telomeres have not been determined. However, 
studies in yeast suggest that loss of H3K4 methylation is an intermediate step in assembly of 
silent chromatin. Telomeres are now known to be sites of active transcription and SMYD3 is 
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located in a region often deleted in ALT-positive, but not telomerase-positive, liposarcomas. 
Decreased H3K4 methylation at ALT telomeres would be predicted to increase 
heterochromatin marks resulting in decreased TERRA expression. However, ALT-positive 
cells show increased TERRA levels, and increased heterochromatin would be expected to 
decrease telomeric recombination, the hallmark of telomere maintenance in ALT. Further 
experimentation will be required to resolve the apparent paradoxes concerning the role of 
H3K4 methylation in telomere maintenance.  
Previous studies of telomere maintenance in liposarcomas have primarily grouped them as 
a single malignancy rather than separating them into histological subtypes. The histological 
bias in telomere maintenance mechanism, as described above, had not been fully realized, 
but inevitably created a strong histotype bias when separating tumors on the basis of TMM 
alone. The importance of this bias was highlighted by a recent publication reporting a gene 
expression signature distinguishing between tumors and cell lines using ALT and 
telomerase (Lafferty-Whyte et al., 2009). In that study, the authors combined expression data 
from cell lines and tumors to identify 297 genes that were differentially expressed between 
ALT and telomerase. When we applied this signature to an independent set of tumors, we 
found that our samples clustered not on the basis of TMM but rather by histological subtype 
(Doyle et al., 2011). A closer analysis of the samples used to generate the published gene 
signature revealed that the cell lines used for the telomerase cohort were primarily of 
epithelial origin and tumors were primarily MYX LS. In contrast, cell lines used for the ALT 
cohort were primarily of mesenchymal origin and tumors were primarily DDLS. Thus, the 
reported cell line signature contained a strong epithelial versus mesenchymal component, 
while the tumor signature was heavily influenced by histological type. Even when we 
applied this published signature within a single histological subtype, DDLS, it failed to 
discriminate tumors on the basis of TMM. This suggests that expression differences between 
ALT-positive and telomerase-positive tumors are subtle, if present at all. 
4.4 TMM and drug sensitivity  
A number of studies have established that inhibition of telomerase and/or compromising 
telomere integrity increase the chemosensitivity of cells. Telomerase-deficient mice exhibit 
an increased sensitivity to DNA damaging agents that is correlated with the level of 
telomere dysfunction (Lee et al., 2001). Because telomere dysfunction leads to widespread 
genome instability, it was proposed that the increased chemosensitivity is a consequence of 
the underlying increase in genome instability. Indeed, reconstitution of telomerase in this 
system resulted in genome stabilization and an increased resistance to DNA damaging 
agents. Experiments carried out using human cell lines have also established an increased 
sensitivity to DNA damaging agents following inhibition of telomerase (Cerone et al., 2006a, 
b; Saretzki, 2003). Furthermore, when telomere integrity is compromised by expressing a 
mutant template RNA that results in repeats unable to recruit the shelterin complex, this 
also results in increased sensitivity to DNA damage (Cerone et al., 2006a). Increased drug 
sensitivity may occur before detectable telomere shortening (Masutomi et al., 2005), raising 
the possibility that telomerase may provide a protective function independent of its role in 
maintaining telomeric DNA arrays (Martinez & Blasco, 2011). For example, telomerase may 
contribute to telomere capping function thereby enhancing telomere stability. Recent work 
has implicated telomerase in modulating the cellular response to DNA damage (Masutomi 
et al., 2005). In this study, reducing telomerase in primary human cells blocked the DNA 
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damage response, thereby rendering cells more sensitive to damage. Exogenous expression 
of mutant hTERT alleles with reduced affinity for telomeric DNA rescued the DNA damage 
response as long as the introduced allele retained catalytic activity. These data suggest that 
telomerase may contribute to the cellular DNA damage response. 
Drugs that target telomerase are increasingly used in cancer therapy with great success 
(Gilley et al., 2005). By reducing telomerase activity, treatment produces shorter telomeres 
and results in apoptosis and tumor shrinkage. In addition, telomerase inhibition increases 
the sensitivity of the cells to other chemotherapeutic agents, either directly through 
telomerase inhibition, as seen with imatinib (Deville et al., 2011), or indirectly via telomere 
shortening, as seen with cisplatin (Uziel et al., 2010). Both mechanisms may depend on the 
intersection of telomere maintenance and DNA repair. Thus ALT-positive tumors may be 
more sensitive than telomerase-positive tumors to DNA-damaging chemotherapies, as they 
possess higher levels of genome instability and lack the anti-apoptotic activity and DNA-
damage protection of telomerase. Alternatively, ALT cells may be more resistant to DNA 
damage as they are able to form clinically significant tumors in a background of high 
genome instability. ALT cells, due to the lack of active telomerase, are expected to be 
entirely refractory to treatment by telomerase inhibitors. The association between telomere 
integrity and sensitivity to DNA damaging chemotherapeutic agents, together with the 
evidence implicating telomerase in the cellular response to DNA damage, is consistent with 
the possibility that TMM may be predictive of tumor response to chemotherapy. 
Current treatments for liposarcomas act through specific over-expressed proteins; for 
example, doxorubicin response correlates with levels of topo2a (Mitchell et al., 2010), and 
nutlin acts as an antagonist to MDM2, a protein highly overexpressed in de-differentiated 
liposarcomas (Muller et al., 2007; Singer et al., 2007). Trabectidin has enhanced activity in 
myxoid/round cell liposarcomas due to the fusion protein (FUS/CHOP) characteristic to 
these malignancies (Conyers et al., 2011). These current treatments are thus expected to be 
independent of TMM. Although studies to date have failed to identify an ALT-specific 
expression profile, we expect that future studies will identify molecular targets specific to 
ALT that will enable more directed treatments. We expect that future treatments will be able 
to leverage knowledge about TMM for improved patient outcome. 
5. Conclusions  
Cancer treatment is steadily moving forward into the exciting realm of personalized 
medicine, targeting unique characteristics of each patient’s disease for improved efficacy. 
Identification of the TMM active in a particular tumor provides a path to this 
personalization, indicating the potential benefit, or lack thereof, for telomerase inhibitors 
and DNA damage-inducing agents. Continuing research into the molecular mechanisms of 
ALT, accounting for inherent histological biases within liposarcoma, will identify molecular 
pathways for ALT-specific anti-cancer treatment that will increase value of TMM 
information in designing patient treatment.  
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